The stock of TFF Pharmaceuticals Inc. (NASDAQ:TFFP) increased by $0.01 on Tuesday to $0.46, up 1.93 percent. The last five days have seen an average of 230,143 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$0.5999. The average number of shares traded over the last 20 days was 187,391, while the average volume over the last 50 days totaled 189,298.
TFFP stock appreciated 34.08% since last month. On 07/24/23, the company’s shares reached a one-month low of $0.3200. The stock touched a high of $6.10 on 01/11/23, after rallying from a low of $0.32 in 52 weeks. The price of TFFP stock has declined by -56.31% or -$0.5999 this year, reaching a new high 4 times. Still, the stock price is down -92.48% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
TFFP stock investors should be aware that TFF Pharmaceuticals Inc. (TFFP) stock had its last reported insider trading activity 0 days ago on Aug 15. On Aug 15, President and CEO Weisman Harlan F acquired 600,000 shares at $0.25 each. This transaction resulted in the insider spending $150,000. On Aug 15, Mikhak Zamaneh added 120,000 shares at a price of US$0.25. After the transaction, the insider now owns 135,000 shares. Director MILLS ROBERT S had earlier bought 40,000 shares on Aug 15 for $0.25 a share. The transaction was completed for $10,000.
Valuation Metrics
Beta for the stock is 1.14. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 33.60, the price-to-book (PB) ratio of 1.00.
Financial Health
For the three months ended March 30, TFF Pharmaceuticals Inc.’s quick ratio was 8.90, while its current ratio was 8.90, indicating its ability to pay off its debt. Based on annual data, it had gross profit of $32.29 million and revenue of $0.5 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. TFFP’s return on assets (ROA) during the last 12 months has been -134.60%. There was a -138.90% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -149.60%.
Earnings Surprise
According to TFF Pharmaceuticals Inc.’s quarterly financial report for the quarter that ended March 30. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $50000.0, while revenues rose by 200.0% to $0.35 million. It was predicted that TFF Pharmaceuticals Inc.’s quarterly earnings would be -$0.19, but it ended up being -$0.23, beating the consensus by 17.40%. EBITDA was -$6.96 million for the quarter. At the end of TFF Pharmaceuticals Inc.’s most recent quarter ended March 30, its liabilities totaled 1.67 million, while its total debt was $0.17 million. Equity owned by shareholders amounts to $36.19 million.
Technical Picture
Here’s a quick look at TFF Pharmaceuticals Inc.’s (TFFP) price momentum from a technical perspective. As of 14 August, the RSI 9-day stood at 64.07%, suggesting the stock is Neutral, with a 103.65% historical volatility rate.
The stochastic %K and %D were 61.48% and 58.99% respectively, while the average true range (ATR) was 0.0572. Based on the 14-day stochastic reading of 50.87%, the RSI (14) reading is 58.51%. On the 9-day MACD Oscillator, the stock is at 0.0255, and the 14-day reading is at 0.0276.
Analyst Ratings
Analysts have assigned TFF Pharmaceuticals Inc. (TFFP) an Buy rating. TFFP is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 3 others recommend it as a buy.
What is TFFP’s price target for the next 12 months?
The current consensus forecast for the stock is between $4.00 and $14.00, with a median target price of $7.00. In analyzing these forecasts, the average price target given by analysts for TFF Pharmaceuticals Inc. (TFFP) is $8.33.
